Income StatementBalance SheetCash FlowSegments
CVS Health logo

CVS Health Balance Sheet Statement

Assets, liabilities, and shareholders' equity

CVS Health holds $252.97B in total assets. Shareholders' equity is $77.5B against $15.2B in total debt. Cash and equivalents total $9.8B. The current ratio is 0.866 and debt-to-equity is 0.197. Based on the Q1 2026 filing.

Total Assets$252.97BTotal Stockholders Equity$77.5BLong Term Debt$65.8BCash And Equivalents$9.8BTotal Current Assets$74.8BTotal Current Liabilities$86.4B
Latest FilingQ1 2026
Report Date2026-05-06
Market Cap$118.99B
P/E Ratio40.58
ROE3.8%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$15.9B$16.5B$17.3B$17.8B$17.6B$16.9B
Other Commercial Liabilities$20.8B$22.4B$23.1B$23.4B$22.4B$22.3B
Accrued Liabilities, Current$20.8B$22.4B$23.1B$23.4B$22.4B$22.3B
Current Portion of Long-Term Debt and Finance Lease Obligations$3.6B$4.4B$6.2B$4.1B$4.1B$2.6B
Operating lease liabilities, current$1.8B$1.9B$1.9B$1.9B$1.7B$1.9B
Total current liabilities$84.6B$89.0B$94.2B$92.7B$88.7B$86.4B

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts receivable, net$36.5B$39.6B$40.7B$43.9B$39.8B$41.0B
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)—$1.2B$961.0M$835.0M—$850.0M
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)$5.7B$5.0B$4.1B$3.7B$3.5B$2.7B
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value$7.5B$4.9B$2.5B$1.8B$2.9B$10.1B
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value$5.7B$5.0B$4.1B$3.7B$3.5B$2.7B
AFS and Trading Securities - Unrealized Loss Position Fair Value$13.2B$9.9B$6.6B$5.4B$6.3B$12.8B
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value$7.5B$4.9B$2.5B$1.8B$2.9B$10.1B
Allowance for Doubtful Accounts$407.0M$392.0M$374.0M$178.0M$182.0M$200.0M
Cash and cash equivalents$8.9B$10.3B$12.0B$9.4B$8.7B$9.8B
Contract assets$9.9B$10.5B$10.5B$11.2B$10.6B$12.5B
Other current assets$3.1B$3.5B$3.4B$3.1B$5.1B$4.3B
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)$8.0B$8.8B$9.1B$10.0B$7.9B$6.7B
Premiums receivable$4.7B$6.2B$5.9B$4.9B$5.8B$7.6B
Inventories$18.1B$17.4B$17.4B$19.0B$19.2B$17.8B
Restricted cash$95.0M$65.0M$43.0M$57.0M$59.0M$14.0M
Total current assets$68.6B$73.2B$75.6B$77.1B$74.7B$74.8B

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss$580.0M$476.0M$396.0M$307.0M$301.0M$305.0M
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss4502.003012.001528.001110.001578.005268.00
Accumulated other comprehensive income (loss)-$120.0M$59.0M$272.0M$416.0M$406.0M$201.0M
Common stock$49.7B$49.8B$50.0B$50.2B$50.4B$50.7B
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding$0.0$0.0$0.0$0.0$0.0$0.0
Investments - Gross Unrealized Losses$13.2B$9.9B$6.6B$5.4B$6.3B$12.8B
Retained earnings$62.8B$63.8B$63.9B$59.1B$61.2B$63.3B
Total liabilities and stockholders' equity$253.2B$255.6B$258.3B$255.3B$253.5B$253.0B
Total stockholders' equity$75.6B$76.9B$77.4B$72.9B$75.2B$77.5B
Treasury stock$36.8B$36.7B$36.8B$36.8B$36.8B$36.7B

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Deferred Tax Assets and Other Non-Current Assets$4.8B$5.2B$5.2B$5.2B$7.1B$7.4B
Goodwill$91.3B$91.2B$91.2B$85.5B$85.5B$85.5B
Equity securities————$333.0M$410.0M
Other intangible assets&#8212;net$27.3B$26.6B$26.2B$26.0B$25.5B$25.1B
Investments$31.3B$31.5B$32.2B$33.7B$34.8B$34.7B
Investments$28.9B$28.9B$29.9B$31.6B$32.7B$32.4B
Operating lease right-of-use assets$15.9B$15.7B$15.5B$15.3B$15.0B$14.7B
Other non-current assets$4.8B$5.2B$5.2B$5.2B$7.1B$7.4B
Property, plant and equipment, net$13.0B$12.9B$12.8B$12.8B$13.1B$13.0B
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)$2.4B$2.6B$2.4B$2.1B$2.1B$2.3B
Operating Lease Right-of-Use Assets in Other Assets$15.9B$15.7B$15.5B$15.3B$15.0B$14.7B
Software and Technology Licenses, Net$4.8B$5.2B$5.2B$5.2B$7.1B$7.4B
Total assets$253.2B$255.6B$258.3B$255.3B$253.5B$253.0B

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Long-Term Debt and Finance Lease Obligations$60.5B$59.0B$57.3B$60.5B$60.5B$60.5B
Liability For Claims And Claims Adjustment Expense And Health Care Organization, Accounts Payable To Third-Party Payor$15.1B$15.1B$15.3B$16.1B$15.4B$15.5B
Other insurance liabilities$1.2B$1.6B$1.1B$1.1B$1.1B$1.1B
Other long-term insurance liabilities$4.9B$4.9B$4.8B$4.8B$4.7B$4.6B
Pharmacy claims and discounts payable$24.2B$25.8B$26.3B$27.1B$26.3B$26.1B
Operating lease liabilities, non-current$14.9B$14.6B$14.3B$14.0B$13.6B$13.3B
Other non-current liabilities$5.4B$5.4B$4.8B$4.8B$6.8B$6.7B
Total liabilities$177.5B$178.5B$180.8B$182.2B$178.2B$175.3B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts Receivable, Allowance for Credit Loss$407.0M$392.0M$374.0M$178.0M$182.0M$200.0M
Effect of changes in discount rate assumptions$1.0M-$2.0M$30.0M$24.0M$20.0M$18.0M
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax$707.0M$547.0M$449.0M$332.0M$331.0M$447.0M
Gross Unrealized Gains$178.0M$246.0M$347.0M$462.0M$449.0M$245.0M
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10—$4.4B$4.5B$4.7B—$5.7B
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10—$4.4B$4.6B$4.8B—$5.7B
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five—$10.7B$11.0B$11.4B—$11.5B
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five—$10.7B$11.1B$11.5B—$11.5B
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10—$2.9B$2.8B$2.8B—$3.1B
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10—$2.7B$2.6B$2.7B—$2.9B
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One—$1.2B$961.0M$835.0M—$850.0M
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One—$1.2B$963.0M$838.0M—$852.0M
Available for sale investments$26.0B$26.0B$26.6B$27.8B$28.7B$28.4B
Common stock, par value (in dollars per share)$0.01$0.01$0.01$0.01$0.01$0.01
Common stock, shares authorized (in shares)3.2B3.2B3.2B3.2B3.2B3.2B
Common stock, shares issued (in shares)1.8B1.8B1.8B1.8B1.8B1.8B
Common Stock, Shares, Outstanding1.3B1.3B1.3B1.3B1.3B1.3B
Debt Securities, Available-for-Sale, Allowance for Credit Loss$0.0$0.0$0.0$0.0$0.0$0.0
Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss$26.6B$26.3B$26.7B$27.7B$28.6B$28.6B
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss$580.0M$476.0M$396.0M$307.0M$301.0M$305.0M
Less than 12 months$7.5B$4.9B$2.5B$1.8B$2.9B$10.1B
12 months or more$5.7B$5.0B$4.1B$3.7B$3.5B$2.7B
Number of Securities, Greater than 12 months4174.003711.003068.002675.002465.002019.00
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss$127.0M$71.0M$53.0M$25.0M$30.0M$142.0M
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss$707.0M$547.0M$449.0M$332.0M$331.0M$447.0M
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions8676.006723.004596.003785.004043.007287.00
Debt Securities, Available-for-Sale, Unrealized Loss Position$13.2B$9.9B$6.6B$5.4B$6.3B$12.8B
Deferred income taxes$3.8B$3.7B$3.6B$3.5B$3.8B$3.8B
Financial Liabilities Fair Value Disclosure————$0.0$0.0
Guarantor obligations, number of leases—60.0060.0060.00—59.00
Gains expected to be reclassified—$16.0M$16.0M$16.0M—$16.0M
Liability for Unpaid Claims and Claims Adjustment Expense, Net$15.0B$14.6B$14.3B$15.3B$15.3B$15.4B
Less: current maturities$3.6B$4.4B$6.2B$4.1B$4.1B$2.6B
Noncontrolling interests in subsidiaries$170.0M$181.0M$172.0M$182.0M$168.0M$181.0M
Number of pharmacy plan members—88000000.0087000000.0087000000.00—88000000.00
Preferred Stock, Par or Stated Value Per Share$0.01$0.01$0.01$0.01$0.01$0.01
Preferred Stock, Shares Authorized100K100K100K100K100K100K
Preferred Stock, Shares Issued000000
Preferred Stock, Shares Outstanding000000
Premium deficiency reserve—$431.0M$902.0M$728.0M—$0.0
Reinsurance recoverable on unpaid losses and loss expenses$81.0M$114.0M$103.0M$94.0M$90.0M$132.0M
Incurred but not reported (IBNR) claims liability, net—$10.7B$10.4B$10.6B—$10.6B
Treasury stock, shares (in shares)518M517M518M516M516M515M
Treasury shares held in trust (in shares)1M1M1M1M1M1M
Treasury shares held in trust$29.0M$29.0M$29.0M$29.0M$29.0M$29.0M
Vendor and manufacturer receivables$13.9B$14.2B$15.2B$17.8B$15.6B$14.1B